These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 32512818

  • 21. Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance.
    Nouri M, Caradec J, Lubik AA, Li N, Hollier BG, Takhar M, Altimirano-Dimas M, Chen M, Roshan-Moniri M, Butler M, Lehman M, Bishop J, Truong S, Huang SC, Cochrane D, Cox M, Collins C, Gleave M, Erho N, Alshalafa M, Davicioni E, Nelson C, Gregory-Evans S, Karnes RJ, Jenkins RB, Klein EA, Buttyan R.
    Oncotarget; 2017 Mar 21; 8(12):18949-18967. PubMed ID: 28145883
    [Abstract] [Full Text] [Related]

  • 22. RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression.
    Li Y, Xie N, Chen R, Lee AR, Lovnicki J, Morrison EA, Fazli L, Zhang Q, Musselman CA, Wang Y, Huang J, Gleave ME, Collins C, Dong X.
    Eur Urol; 2019 Aug 21; 76(2):157-166. PubMed ID: 30910347
    [Abstract] [Full Text] [Related]

  • 23. FOXA1 inhibits prostate cancer neuroendocrine differentiation.
    Kim J, Jin H, Zhao JC, Yang YA, Li Y, Yang X, Dong X, Yu J.
    Oncogene; 2017 Jul 13; 36(28):4072-4080. PubMed ID: 28319070
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPC.
    Lee CF, Chen YA, Hernandez E, Pong RC, Ma S, Hofstad M, Kapur P, Zhau H, Chung LW, Lai CH, Lin H, Lee MS, Raj GV, Hsieh JT.
    Clin Transl Med; 2022 Feb 13; 12(2):e695. PubMed ID: 35184376
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Preclinical Models of Neuroendocrine Prostate Cancer.
    Cacciatore A, Albino D, Catapano CV, Carbone GM.
    Curr Protoc; 2023 May 13; 3(5):e742. PubMed ID: 37166213
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma.
    Sulsenti R, Frossi B, Bongiovanni L, Cancila V, Ostano P, Fischetti I, Enriquez C, Guana F, Chiorino G, Tripodo C, Pucillo CE, Colombo MP, Jachetti E.
    Front Immunol; 2021 May 13; 12():622001. PubMed ID: 33737929
    [Abstract] [Full Text] [Related]

  • 36. Molecular events in neuroendocrine prostate cancer development.
    Wang Y, Wang Y, Ci X, Choi SYC, Crea F, Lin D, Wang Y.
    Nat Rev Urol; 2021 Oct 13; 18(10):581-596. PubMed ID: 34290447
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Targeting SOX4/PCK2 signaling suppresses neuroendocrine trans-differentiation of castration-resistant prostate cancer.
    Jing N, Tao Z, Du X, Wen Z, Gao WQ, Dong B, Fang YX.
    Biol Direct; 2024 Jul 16; 19(1):56. PubMed ID: 39014441
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.